Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems is a strong investment opportunity due to their reported better than expected gross margins, significant increase in revenues and net income, strong financial outlook for the remainder of 2026, and ability to fund operations with their current cash and short term equivalents. With a Buy rating and a 12-month price target of $32 per diluted share, based on a risk-adjusted net present value, DCTH's strong financials and multiple indications in their pipeline make them a compelling investment opportunity. However, risks such as commercialization, pricing, reimbursement, competition, supply constraints, tariffs, and access to financing should be considered.

Delcath Systems is facing a revenue gap due to the 340B pricing of their HEPZATO KIT, leading to lower effective ASP. Despite a 30% YoY increase in HEPZATO KIT volume, revenue only grew by 21% YoY. However, with strong 1H26 revenue performance, management has raised their FY2026 revenue guidance and reported a healthy level of new patient starts at existing sites. Their focus on strengthening referral networks and physician awareness may lead to growth opportunities for the company, but competition from other oncology companies such as AtriCure, Boston Scientific, Dexcom, Glaukos, Insulet, Merit Medical Systems, Penumbra, and iRhythm Technologies could impact their market share.